Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Leerink Partners Initiates Coverage On NeuroPace with Outperform Rating, Announces Price Target of $22

Author: Benzinga Newsdesk | January 30, 2024 09:15am

Leerink Partners analyst Mike Kratky initiates coverage on NeuroPace (NASDAQ:NPCE) with a Outperform rating and announces Price Target of $22.

Posted In: NPCE